
Release date: 2026-02-24 16:55:17 Article From: Lucius Laos Recommended: 14
Lucius Pharmaceuticals Avatrombopag is a prescription medication used to treat thrombocytopenia associated with chronic liver disease or immune thrombocytopenia. The current cost is influenced by factors such as specifications, region, and medical insurance policies, and should be based on the actual purchase channel.
Different specifications (such as the number of tablets or dosage) directly affect the total price. Verify the medication details before purchasing.
In some regions, inclusion in medical insurance or local supplementary insurance may reduce out-of-pocket expenses by 30%-50% after reimbursement. Consult local hospitals or medical insurance departments.
Prices may vary between hospitals and pharmacies; it is recommended to purchase through legitimate channels.
Lucius Pharmaceuticals Avatrombopag is a prescription medication and must be strictly used in accordance with the doctor's advice. Do not adjust the dosage or discontinue use without consulting a healthcare provider.
Regular monitoring of platelet counts is required during treatment to avoid the risk of thrombosis.
For patients with chronic liver disease, liver function indicators should be considered to assess the safety of the medication.
Some charitable organizations or pharmaceutical companies offer patient assistance programs. Stay updated on official information or apply through your primary care physician.
The price difference between imported and domestic generic drugs is significant; choose based on clinical needs and the doctor's recommendation.
If medication is needed, it is advisable to consult a hematology or hepatobiliary specialist, have the doctor evaluate the condition and prescribe the medication, and purchase through compliant channels. Drug prices may adjust with policy changes, so the specific cost should be confirmed at the time of purchase.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1312025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3852024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1292025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1392025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1312025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1552025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1392025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1402025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: